ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 742,97
0,03%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. UroGen Pharma Ltd (URGN)

  7. UroGen Pharma Ltd (URGN) Actualités

URGN

UroGen Pharma (URGN)

UroGen Pharma Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:URGN
DateHeureSourceTitreSymboleSociété
22/05/202414h00Business WireUroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:URGNUroGen Pharma Ltd
13/05/202414h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
13/05/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
13/05/202414h00Business WireUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsNASDAQ:URGNUroGen Pharma Ltd
07/05/202414h00Business WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
05/05/202418h20Business WireNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyNASDAQ:URGNUroGen Pharma Ltd
04/05/202421h20Business WireUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024NASDAQ:URGNUroGen Pharma Ltd
04/05/202417h50Business WireNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialNASDAQ:URGNUroGen Pharma Ltd
03/05/202414h00Business WireUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024NASDAQ:URGNUroGen Pharma Ltd
17/04/202418h02Business WireUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
15/04/202414h00Business WireUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
03/04/202414h00Business WireUroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNASDAQ:URGNUroGen Pharma Ltd
14/03/202413h00Business WireUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102NASDAQ:URGNUroGen Pharma Ltd
08/03/202414h00Business WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
04/03/202414h00Business WireUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:URGNUroGen Pharma Ltd
26/02/202414h00Business WireUroGen Pharma to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:URGNUroGen Pharma Ltd
12/02/202423h47Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
03/02/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
01/02/202416h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
24/01/202414h00Business WireUroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102NASDAQ:URGNUroGen Pharma Ltd
17/01/202414h00Business WireUroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
11/01/202414h00Business WireUroGen Pharma to Participate in the B. Riley Healthcare ConferenceNASDAQ:URGNUroGen Pharma Ltd
14/11/202322h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:URGNUroGen Pharma Ltd
14/11/202314h00Business WireUroGen Pharma Reports Third Quarter 2023 Financial ResultsNASDAQ:URGNUroGen Pharma Ltd
13/11/202314h00Business WireUroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic OncologyNASDAQ:URGNUroGen Pharma Ltd
07/11/202314h00Business WireUroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023NASDAQ:URGNUroGen Pharma Ltd
03/10/202314h00Business WireFollowing Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024NASDAQ:URGNUroGen Pharma Ltd
18/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:URGNUroGen Pharma Ltd
11/09/202313h00GlobeNewswire Inc.Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of DirectorsNASDAQ:URGNUroGen Pharma Ltd
08/09/202322h16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:URGNUroGen Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:URGN

Dernières Valeurs Consultées

NASDAQ
AAPL
Apple
NYSE
KO
Coca Cola
COIN
BTCUSD
Bitcoin
EU
ACA
Credit Agricole
EU
RI
Pernod Ricard
NASDAQ
AMZN
Amazon.com
NYSE
NKE
Nike
NYSE
MCD
McDonalds
EU
MC
Lvmh Moet Hennessy Louis...
EU
BNP
BNP Paribas
EU
VIV
Vivendi
NYSE
JPM
JP Morgan Chase
EU
AF
Air FranceKLM
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés